Results 211 to 220 of about 87,925 (315)

Trends in the Dispensing of Oral Anti‐Cancer Medications Across Australia Over 10 Years

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 4, April 2025.
ABSTRACT Purpose Oral anti‐cancer medications (OAMs) are easily administered yet high‐risk treatments. Few studies have investigated national and subnational trends in OAM dispensing. We aimed to examine 10‐year trends in Australia's OAM dispensing at the national level as well as by state/territory and medication type/class.
Michael James Leach, Emily Griffin, Sinead Hickmott, Holly Atkinson, Louise Bettiol, Eli Ristevski   +5 more
wiley   +1 more source

Molecular response of a patient with e19a2-positive chronic myeloid leukemia to flumatinib: a case report and literature review. [PDF]

Front Med (Lausanne)
Feng Y, Wang H, Zhang L, Gong J, Liu X, Mu C, Qiao J, Meng H, Zhang Y.   +8 more
europepmc   +1 more source

Imatinib (STI571) Provides Only Limited Selectivity for CML Cells and Treatment Might Be Complicated by SilentBCR-ABLGenes [PDF]

, 2003
Guanchao Jiang, Fan Yang, Marilyn M. Li, Karen Weissbecker, Sherrie Price, Chan Kim, Vincent F. La Russa, Hana Safah, Melanie Ehrlich   +8 more
openalex   +1 more source

PDBe tools for an in‐depth analysis of small molecules in the Protein Data Bank

Protein Science, Volume 34, Issue 4, April 2025.
Abstract The Protein Data Bank (PDB) is the primary global repository for experimentally determined 3D structures of biological macromolecules and their complexes with ligands, proteins, and nucleic acids. PDB contains over 47,000 unique small molecules bound to the macromolecules.
Preeti Choudhary, Ibrahim Roshan Kunnakkattu, Sreenath Nair, Dare Kayode Lawal, Ivanna Pidruchna, Marcelo Querino Lima Afonso, Jennifer R. Fleming, Sameer Velankar   +7 more
wiley   +1 more source

Identification of a novel <i>NRF1</i>::<i>PDGFRA</i> fusion in myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions. [PDF]

Front Oncol
Liu J, Feng Y, Zhang Y, Xiao Y, Liu X, Xiao T, Zou J, Fan K, Lu L, Yang X, Gong J.   +10 more
europepmc   +1 more source

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment [PDF]

, 2003
Ravi Bhatia, Melissa Holtz, Ning Niu, Rachel Gray, David S. Snyder, Charles L. Sawyers, Daniel A. Arber, Marilyn L. Slovak, Stephen J. Forman   +8 more
openalex   +1 more source

The new big is small: Leveraging knowledge from small trials for rare disease drug development: Blarcamesine for Rett syndrome

British Journal of Clinical Pharmacology, Volume 91, Issue 4, Page 1049-1063, April 2025.
Big data in drug development may not satisfactorily address the demands of precision medicine in a rare disease population, making the use of smaller clinical trials necessary. Consequently, the use of innovative design and analysis of these clinical trials using model‐informed approaches have become indispensable.
Ene I. Ette, Emmanuel O. Fadiran, Christopher Missling, Edward Hammond   +3 more
wiley   +1 more source

Acute abdomen due to a perforated giant GIST of the small intestine evolving slowly for 6 years: A case report. [PDF]

Int J Surg Case Rep
Ben Mahmoud A, Hammami M, Atri S, Sebai A, Haddad A, Kacem M.   +5 more
europepmc   +1 more source

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

, 2003
Susan Branford, Zbigniew Rudzki, Sonya Walsh, Ian Parkinson, Andrew Grigg, Jeff Szer, Kerry Taylor, Richard Herrmann, John F. Seymour, Chris Arthur, David Joske, Kevin Lynch, Timothy P. Hughes   +12 more
openalex   +1 more source

Imatinib administration in two patients with liver metastases from GIST and severe jaundice [PDF]

, 2003
Tommaso De Pas, Romano Danesi, Chiara Catania, Giuseppe Curigliano, Filippo de Braud   +4 more
openalex   +1 more source